115 related articles for article (PubMed ID: 34027868)
21. The promotion of nanoparticle delivery to two populations of gastric cancer stem cells by CD133 and CD44 antibodies.
Chen H; Lin J; Shan Y; Zhengmao L
Biomed Pharmacother; 2019 Jul; 115():108857. PubMed ID: 31048191
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic significance of putative stem cell markers, CD44 and nestin, in gastric adenocarcinoma.
Dhingra S; Feng W; Brown RE; Zhou Z; Khoury T; Zhang R; Tan D
Int J Clin Exp Pathol; 2011; 4(8):733-41. PubMed ID: 22135720
[TBL] [Abstract][Full Text] [Related]
23. [Multiparametric flow cytometry analyzes the expressions of immunophenotype CD133, CD34, CD44 in lung cancer naive cells].
Liu D; Li WM; Mo XM; Liu LX; Wang Y; Che GW; Wu Z; Gou JL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):827-31. PubMed ID: 19024325
[TBL] [Abstract][Full Text] [Related]
24. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
25. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
26. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G
Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186
[TBL] [Abstract][Full Text] [Related]
27. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
[TBL] [Abstract][Full Text] [Related]
28. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of expression of cancer stem cell markers and fusion gene in synovial sarcoma: Insights into histogenesis and pathogenesis.
Zhou Y; Chen D; Qi Y; Liu R; Li S; Zou H; Lan J; Ju X; Jiang J; Liang W; Shen Y; Pang L; Li F
Oncol Rep; 2017 Jun; 37(6):3351-3360. PubMed ID: 28498445
[TBL] [Abstract][Full Text] [Related]
30. Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer.
Zhang X; Hua R; Wang X; Huang M; Gan L; Wu Z; Zhang J; Wang H; Cheng Y; Li J; Guo W
Oncotarget; 2016 Mar; 7(9):9815-31. PubMed ID: 26769843
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models.
Zhao Q; Zhou H; Liu Q; Cao Y; Wang G; Hu A; Ruan L; Wang S; Bo Q; Chen W; Hu C; Xu D; Tao F; Cao J; Ge Y; Yu Z; Li L; Wang H
Oncotarget; 2016 Jul; 7(30):47431-47443. PubMed ID: 27329727
[TBL] [Abstract][Full Text] [Related]
32. CD133+ CD44+ subgroups may be human small intestinal stem cells.
Hou NY; Yang K; Chen T; Chen XZ; Zhang B; Mo XM; Hu JK
Mol Biol Rep; 2011 Feb; 38(2):997-1004. PubMed ID: 20526812
[TBL] [Abstract][Full Text] [Related]
33. CD44 is functionally crucial for driving lung cancer stem cells metastasis through Wnt/β-catenin-FoxM1-Twist signaling.
Su J; Wu S; Wu H; Li L; Guo T
Mol Carcinog; 2016 Dec; 55(12):1962-1973. PubMed ID: 26621583
[TBL] [Abstract][Full Text] [Related]
34. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
35. Microenvironmentally-driven Plasticity of CD44 isoform expression determines Engraftment and Stem-like Phenotype in CRC cell lines.
Dinger TF; Chen O; Dittfeld C; Hetze L; Hüther M; Wondrak M; Löck S; Eicheler W; Breier G; Kunz-Schughart LA
Theranostics; 2020; 10(17):7599-7621. PubMed ID: 32685007
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and Clinical Value of CD44 and CD133 in Esophageal Cancer: A Systematic Review and Meta-analysis.
Kamil Mohammed Al-Mosawi A; Cheshomi H; Hosseinzadeh A; M Matin M
Iran J Allergy Asthma Immunol; 2020 Apr; 19(2):105-116. PubMed ID: 32372624
[TBL] [Abstract][Full Text] [Related]
37. CD133 marks for colorectal adenocarcinoma.
Chew MF; Teoh KH; Cheah PL
Malays J Pathol; 2012 Jun; 34(1):25-8. PubMed ID: 22870594
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
39. Association Between CD133 Expression and Prognosis in Human Lung Adenocarcinoma.
Yamashita N; Oyama T; So T; Miyata T; Yoshimatsu T; Nakano R; Matsunaga W; Gotoh A
Anticancer Res; 2021 Feb; 41(2):905-910. PubMed ID: 33517296
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.
Han Z; Chen Z; Zheng R; Cheng Z; Gong X; Wang D
World J Surg Oncol; 2015 Feb; 13():56. PubMed ID: 25889325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
